Abstract
GLYCEMIC EFFECT OF FIXED DOSE COMBINATION OF TENELIGLIPTIN AND METFORMIN IN TYPE-2 DIABETES MELLITUS PATIENTS

Priti Singh, Pooja Agrawal*, Virendra Kushwaha, Ambrish Gupta, Amit Kumar, Saurabh Agarwal and Mahesh Chandra Bindal

ABSTRACT

Background: Teneligliptin is a potent, long acting and highly selective third generation dipeptidyl peptidase-4 (DPP-4) inhibitor recently introduced in India. The main objective of present study was to evaluate the effect of Teneligliptin and Metformin fixed dose combination on glycemic parameters in the treatment of type-2 diabetes mellitus in India. Material and Methods: In this prospective observational study total 70 patients were screened and among them 40 patients were eligible to be enrolled in our study. Teneligliptin (20 mg/day) Metformin (500 mg) fixed dose combination was prescribed in patients with type-2 diabetes and changes in the glycemic parameters were observed at every 4 weeks for 16 weeks treatment which were compared with the baseline. Analysis was done using t-test and a p-value of <0.05 was considered significant. Results: There was statistically significant improvement in mean HbA1c, FBG, and PPBG with teneligliptin and metformin fixed dose therapy. The change in HbA1c level from baseline was −0.79% (7.9 to 7.1%) at 16 weeks of treatment. Percentage of patients achieving target HbA1C (≤7) was 37.5% at 16 weeks. Reduction was also significant (P<0.001) in FBG -32.4mg/dl (149.8-117.4mg/dl) and 2h PPBG 54.3mg/dl (234-179.7mg/dl) at 16 weeks of treatment. There were no cases of hypoglycemia or weight gain reported in the present study. Conclusions: Teneligliptin and Metformin fixed dose combination showed significant improvement in all glycemic parameters and well tolerated at the end of the study period in patients with type-2 diabetes.

Keywords: Teneligliptin, Diabetes Mellitus, DPP-4 inhibitor, HbA1c.


[Full Text Article]   [Download Certificate]

Login





Forgot Password  |  Register

Indexing

Best Paper Awards

European Journal of Biomedical and Pharmaceutical Sciences (EJBPS) will give best paper award in every issue in the form of money along with certificate to promote research activity of scholar.

Best Article of current issue :

Dr. Dhrubo Jyoti Sen

Download Article : Click here

News & Updation

  • EJBPS: JUNE ISSUE PUBLISHED

    JUNE 2024 Issue has been successfully launched on 1 JUNE 2024.

  • EJBPS New Impact Factor

    EJBPS Impact Factor has been Increased to 7.482 for Year 2024.

  • Index Copernicus Value

    EJBPS Received Index Copernicus Value 77.3, due to High Quality Publication in EJBPS at International Level

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.

    .

  • Article Invited for Publication

    Dear Researcher, Article Invited for Publication  in EJBPS coming Issue.

     

UG/PG/Ph.D Research Publication

Research Scholar of UG/PG/Ph.D can Submit their Research Article/Review Article/Case Study/Short Communication for Publication in EJBPS

Downloads

Copyright From

Covering Letter

                        Author Instruction 
 

PLAGERLUM REPORT